Veterinary Medicine Information website

Doxycycline 75 % Kela 750 mg/g Poudre orale

Authorised
  • Doxycycline hyclate
Download as PDF

Product identification

Medicine name:
Doxycycline 75 % Kela 750 mg/g Poudre orale
Active substance:
  • Doxycycline hyclate
Target species:
  • Pig
Route of administration:
  • In-feed use
  • In drinking water use

Product details

Active substance and strength:
  • Doxycycline hyclate
    932.80
    milligram(s)
    /
    1.00
    gram(s)
Pharmaceutical form:
  • Oral powder
Withdrawal period by route of administration:
  • In-feed use
    • Pig
      • Meat and offal
        5
        day
  • In drinking water use
    • Pig
      • Meat and offal
        5
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01AA02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Luxembourg
Available in:
  • Luxembourg
Package description:
  • Doxycycline 75 % Kela 750 mg/g Bag of 100 g
  • Doxycycline 75 % Kela 750 mg/g Bag of 133 g
  • Doxycycline 75 % Kela 750 mg/g Bag of 500 g
  • Doxycycline 75 % Kela 750 mg/g Bag of 667 g
  • Doxycycline 75 % Kela 750 mg/g Bag of 1000 g
  • Doxycycline 75 % Kela 750 mg/g Bag of 1333 g
  • Doxycycline 75 % Kela 750 mg/g Bag of 1333 g

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • KELA Kempisch Laboratorium Kela Laboratoria
Marketing authorisation date:
Manufacturing sites for batch release:
  • KELA Kempisch Laboratorium Kela Laboratoria
Responsible authority:
  • Ministry Of Health And Social Security
Authorisation number:
  • V 188/18/05/1689
Date of authorisation status change:

Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 4/03/2023
Download

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 4/03/2023
Download